CR20210493A - SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE - Google Patents
SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNEInfo
- Publication number
- CR20210493A CR20210493A CR20210493A CR20210493A CR20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pbmcs
- immune response
- biomolecules
- modify
- delivery
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title abstract 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0648—Splenocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente solicitud proporciona células sanguíneas periféricas mononucleares (PBMCs) que comprenden un antígeno, métodos de producción de dichas PBMCs, y métodos de utilización de dichas PBMCs, tales como la modulación de una respuesta inmune en un individuo. En ciertas realizaciones, las PBMCs están acondicionadas al incubar la PBMC en presencia de un coadyuvante
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962812225P | 2019-02-28 | 2019-02-28 | |
EP19161964 | 2019-03-11 | ||
US201962841089P | 2019-04-30 | 2019-04-30 | |
US201962886799P | 2019-08-14 | 2019-08-14 | |
US201962933304P | 2019-11-08 | 2019-11-08 | |
US201962948732P | 2019-12-16 | 2019-12-16 | |
PCT/US2020/020194 WO2020176789A1 (en) | 2019-02-28 | 2020-02-27 | Delivery of biomolecules to pbmcs to modify an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210493A true CR20210493A (es) | 2022-01-17 |
Family
ID=72238527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210493A CR20210493A (es) | 2019-02-28 | 2020-02-27 | SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE |
Country Status (17)
Country | Link |
---|---|
US (1) | US11692168B2 (es) |
EP (1) | EP3931309A4 (es) |
JP (1) | JP2022522351A (es) |
KR (1) | KR20210134353A (es) |
CN (1) | CN114127267A (es) |
AU (1) | AU2020228648A1 (es) |
BR (1) | BR112021016903A2 (es) |
CA (1) | CA3131701A1 (es) |
CL (1) | CL2021002258A1 (es) |
CO (1) | CO2021012581A2 (es) |
CR (1) | CR20210493A (es) |
IL (1) | IL285809A (es) |
MX (1) | MX2021010320A (es) |
PE (1) | PE20220379A1 (es) |
SG (1) | SG11202109333SA (es) |
TW (1) | TW202045717A (es) |
WO (1) | WO2020176789A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
BR112021016903A2 (pt) | 2019-02-28 | 2021-11-03 | Sqz Biotechnologies Co | Administração de biomoléculas a pbmcs para modificação de uma resposta imune |
CA3136296A1 (en) | 2019-04-08 | 2020-10-15 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
CA3140029A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
AU2021272340A1 (en) * | 2020-05-11 | 2022-12-08 | F. Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
JP2023539370A (ja) * | 2020-09-02 | 2023-09-13 | スクイーズ バイオテクノロジーズ カンパニー | 有核細胞を使用してタンパク質に対するhla非依存的な免疫応答を刺激する方法 |
EP4271711A1 (en) | 2020-12-29 | 2023-11-08 | SQZ Biotechnologies Company | Methods for treating cancers with modified pbmcs |
CN116801719A (zh) * | 2020-12-29 | 2023-09-22 | Sqz生物技术公司 | 用于pbmc冷冻保存的调配物 |
US20220296691A1 (en) | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
CA3203709A1 (en) | 2020-12-29 | 2022-07-07 | Sqz Biotechnologies Company | Formulations of activating antigen carriers |
WO2023003907A1 (en) * | 2021-07-19 | 2023-01-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Cellular therapies for cancer by inhibition of monocarboxylate transporter 11 |
EP4377447A1 (en) | 2021-07-29 | 2024-06-05 | SQZ Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
WO2023087009A1 (en) | 2021-11-11 | 2023-05-19 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
WO2024026491A2 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Enhanced antigen presenting cell formulations |
WO2024026492A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Methods for treating cancer with enhanced antigen presenting cells |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2502621C3 (de) | 1975-01-23 | 1978-09-14 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Messung elastischer und dielektrischer Eigenschaften der Membran lebender Zellen |
US4376634A (en) | 1980-05-30 | 1983-03-15 | Mallinckrodt, Inc. | Assay kit having syringe, dilution device and reagents within sealed container |
FR2569477B1 (fr) | 1984-08-24 | 1987-01-02 | Descartes Universite Rene | Appareil et procede pour la determination de la deformabilite des globules rouges du sang |
JP2720161B2 (ja) | 1988-02-01 | 1998-02-25 | 株式会社アドバンス | 細胞変形能測定装置 |
JP2685544B2 (ja) | 1988-11-11 | 1997-12-03 | 株式会社日立製作所 | 血液フィルタおよび血液検査方法並びに血液検査装置 |
JP2532707B2 (ja) | 1990-03-08 | 1996-09-11 | 佑二 菊池 | 血液回路及びこれを用いた血液測定装置及び血液測定方法 |
AU2002252073A1 (en) | 2001-02-22 | 2002-09-12 | The Scepens Eye Research Institute, Inc. | Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions |
CN1604795B (zh) | 2001-08-17 | 2010-05-26 | 科勒制药股份公司 | 具有提高的活性的组合基序免疫刺激寡肽 |
WO2003020039A1 (en) | 2001-08-28 | 2003-03-13 | Rush-Presbyterian-St. Luke's Medical Center | Immune tolerance to predetermined antigens |
EP2365325A1 (en) | 2002-06-05 | 2011-09-14 | Panasonic Corporation | Device for measuring extracellular potential and method of manufacturing the device |
US20060134067A1 (en) | 2003-02-18 | 2006-06-22 | Maxcyte, Inc. | Loading of cells with antigens by electroporation |
AU2003290460A1 (en) | 2003-12-24 | 2005-07-14 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
EP1746976B1 (en) | 2004-05-03 | 2017-01-11 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery |
US7968335B2 (en) | 2004-06-17 | 2011-06-28 | Ken Nakata | Cell culturing method using biomechanical stimulation loading and system therefor |
CN100591761C (zh) | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
US20060134772A1 (en) | 2004-11-18 | 2006-06-22 | The Regents Of The University Of California | System for locating cells and for cellular analysis |
US7704743B2 (en) | 2005-03-30 | 2010-04-27 | Georgia Tech Research Corporation | Electrosonic cell manipulation device and method of use thereof |
MX2007014474A (es) * | 2005-05-17 | 2008-02-07 | Univ Connecticut | Composiciones y metodos para inmunomodulacion en un organismo. |
WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
US8293524B2 (en) | 2006-03-31 | 2012-10-23 | Fluxion Biosciences Inc. | Methods and apparatus for the manipulation of particle suspensions and testing thereof |
US20070249038A1 (en) | 2006-04-21 | 2007-10-25 | Andrea Adamo | Microfluidic device for single cell targeted operations |
JP2010500921A (ja) | 2006-08-17 | 2010-01-14 | マサチューセッツ・インスティテュート・オブ・テクノロジー | マイクロ流体インジェクションのための方法と装置 |
WO2008098094A1 (en) | 2007-02-06 | 2008-08-14 | Network Biosystems, Inc. | Devices and methods for the performance of miniaturized in vitro assays |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
GB0718160D0 (en) | 2007-09-18 | 2007-10-24 | Medical Res Council | Methods |
WO2009069418A1 (ja) | 2007-11-28 | 2009-06-04 | Konica Minolta Opto, Inc. | 血液流動性計測装置及び血液流動性計測方法 |
US20090280518A1 (en) | 2008-05-12 | 2009-11-12 | Massachusetts Institute Of Technology | System for high throughput measurement of mechanical properties of cells |
JP5137129B2 (ja) | 2008-07-23 | 2013-02-06 | 国立大学法人山口大学 | 血液細胞の力学的特性測定装置 |
US9115340B2 (en) | 2008-08-08 | 2015-08-25 | Agency For Science Technology & Research | Microfluidic continuous flow device |
CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
US9364831B2 (en) | 2009-08-08 | 2016-06-14 | The Regents Of The University Of California | Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting |
ES2600932T3 (es) | 2009-10-27 | 2017-02-13 | Erytech Pharma | Composición para inducir una tolerancia inmunitaria específica |
CN102791616B (zh) | 2009-12-23 | 2015-07-29 | 西托维拉公司 | 用于粒子过滤的系统和方法 |
US20110293558A1 (en) | 2010-03-22 | 2011-12-01 | Massachusetts Institute Of Technology | Material properties of t cells and related methods and compositions |
ES2924027T3 (es) | 2010-11-25 | 2022-10-04 | Imcyse Sa | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
AU2012326203B2 (en) | 2011-10-17 | 2017-11-30 | Massachusetts Institute Of Technology | Intracellular delivery |
WO2013185032A1 (en) | 2012-06-07 | 2013-12-12 | President And Fellows Of Harvard College | Nanotherapeutics for drug targeting |
WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
WO2015023982A1 (en) | 2013-08-16 | 2015-02-19 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
RU2739794C2 (ru) * | 2014-10-31 | 2020-12-28 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
CN107002089B (zh) | 2014-11-14 | 2021-09-07 | 麻省理工学院 | 化合物和组合物向细胞中的破坏和场实现的递送 |
CA2971626A1 (en) | 2015-01-12 | 2016-07-21 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
CA2988996A1 (en) | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Delivery of materials to anucleate cells |
EP3344747B1 (en) | 2015-09-04 | 2022-11-09 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules mediated by a surface with pores |
WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
ES2964746T3 (es) | 2015-12-30 | 2024-04-09 | Celgene Corp | Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo |
JP7033535B2 (ja) | 2016-01-12 | 2022-03-10 | スクイーズ バイオテクノロジーズ カンパニー | 複合体の細胞内送達 |
CA3023099A1 (en) | 2016-05-03 | 2017-11-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to induce tolerance |
CN109415741A (zh) | 2016-05-03 | 2019-03-01 | Sqz生物技术公司 | 细胞内递送生物分子以诱导耐受性 |
US11422127B2 (en) * | 2016-12-07 | 2022-08-23 | Albany Medical College | Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens |
US20210317187A1 (en) | 2017-12-05 | 2021-10-14 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to modulate antibody production |
US20200332243A1 (en) | 2017-12-20 | 2020-10-22 | Sqz Biotechnologies Company | System for delivery of a payload into a cell |
TW202003019A (zh) | 2018-03-12 | 2020-01-16 | 美商Sqz生物科技公司 | 細胞內投遞生物分子以修改免疫反應之方法 |
WO2019178005A2 (en) * | 2018-03-12 | 2019-09-19 | Sqz Biotechnologies Company | Methods for treating hpv-associated diseases |
US20210113628A1 (en) | 2018-03-12 | 2021-04-22 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to modify immune response |
CA3115245A1 (en) | 2018-10-04 | 2020-04-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to enhance antigen presenting cell function |
US20220105166A1 (en) | 2019-01-25 | 2022-04-07 | Sqz Biotechnologies Company | Anucleate cell-derived vaccines |
BR112021016903A2 (pt) | 2019-02-28 | 2021-11-03 | Sqz Biotechnologies Co | Administração de biomoléculas a pbmcs para modificação de uma resposta imune |
CA3136296A1 (en) | 2019-04-08 | 2020-10-15 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
-
2020
- 2020-02-27 BR BR112021016903A patent/BR112021016903A2/pt unknown
- 2020-02-27 AU AU2020228648A patent/AU2020228648A1/en active Pending
- 2020-02-27 JP JP2021550182A patent/JP2022522351A/ja active Pending
- 2020-02-27 EP EP20762663.1A patent/EP3931309A4/en active Pending
- 2020-02-27 US US16/803,937 patent/US11692168B2/en active Active
- 2020-02-27 CN CN202080031336.8A patent/CN114127267A/zh active Pending
- 2020-02-27 WO PCT/US2020/020194 patent/WO2020176789A1/en unknown
- 2020-02-27 MX MX2021010320A patent/MX2021010320A/es unknown
- 2020-02-27 CR CR20210493A patent/CR20210493A/es unknown
- 2020-02-27 SG SG11202109333SA patent/SG11202109333SA/en unknown
- 2020-02-27 CA CA3131701A patent/CA3131701A1/en active Pending
- 2020-02-27 KR KR1020217030867A patent/KR20210134353A/ko unknown
- 2020-02-27 PE PE2021001420A patent/PE20220379A1/es unknown
- 2020-02-27 TW TW109106460A patent/TW202045717A/zh unknown
-
2021
- 2021-08-23 IL IL285809A patent/IL285809A/en unknown
- 2021-08-26 CL CL2021002258A patent/CL2021002258A1/es unknown
- 2021-09-24 CO CONC2021/0012581A patent/CO2021012581A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202045717A (zh) | 2020-12-16 |
PE20220379A1 (es) | 2022-03-18 |
US11692168B2 (en) | 2023-07-04 |
CA3131701A1 (en) | 2020-09-03 |
WO2020176789A1 (en) | 2020-09-03 |
EP3931309A4 (en) | 2022-12-21 |
EP3931309A1 (en) | 2022-01-05 |
JP2022522351A (ja) | 2022-04-18 |
MX2021010320A (es) | 2021-11-12 |
CO2021012581A2 (es) | 2022-01-17 |
US20200318066A1 (en) | 2020-10-08 |
SG11202109333SA (en) | 2021-09-29 |
AU2020228648A1 (en) | 2021-10-14 |
CL2021002258A1 (es) | 2022-06-17 |
KR20210134353A (ko) | 2021-11-09 |
IL285809A (en) | 2021-10-31 |
CN114127267A (zh) | 2022-03-01 |
US20240132839A1 (en) | 2024-04-25 |
BR112021016903A2 (pt) | 2021-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210493A (es) | SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE | |
PH12020551436A1 (en) | Intracellular delivery of biomolecules to modify immune response | |
PH12020551437A1 (en) | Methods for treating hpv-associated diseases | |
PH12019501227A1 (en) | Synthetic immune receptors and methods of use thereof | |
MX2020008390A (es) | Receptores de linfocitos t no restringidos a antígenos leucocitarios humanos (hla) y usos de los mismos. | |
WO2019008123A3 (en) | CELLS, VERTEBRATES, POPULATIONS AND METHODS | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
EP4257199A3 (en) | Humanized anti-human-pd-1 antibody | |
BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
MX2023005612A (es) | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. | |
BR112021021843A2 (pt) | Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas | |
WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
CY1120220T1 (el) | Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση | |
PH12020552181A1 (en) | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof | |
CU20210041A7 (es) | Péptidos inmunogénicos con motivos de oxidorreductasa | |
AR119997A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
CO2022007238A2 (es) | Terapia de células t del receptor de antígeno quimérico | |
ZA202205927B (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
WO2018120843A9 (zh) | 一种三功能分子及其应用 | |
WO2019028422A9 (en) | METHODS OF ACTIVATION OF IMMUNE CELLS | |
WO2019066617A3 (ko) | 항 c-met 항체 및 이의 용도 | |
MX2022000379A (es) | Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas. | |
EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения | |
WO2022051437A3 (en) | Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells |